CTRI/2009/091/000232Other3 期
Open-Label Trial to Determine the Long-Term Safety ofSafinamide in Parkinsons Disease Patients
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
- Merck Serono
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. The subject has completed a previous clinical study with safinamide in PD, and;
- •2. The subject successfully completed all trial requirements of the antecedent trial, and;
- •3. If female, they must be either post-menopausal for at least 2 years, surgically sterilized or have undergone hysterectomy or, if of child bearing potential they must be willing to avoid pregnancy by using an adequate method of contraception for four weeks prior to, during and four weeks after the last dose of study medication. For the purpose of this trial, women of childbearing potential are defined as all female subjects after puberty unless they are postmenopausal for at least two years, are surgically sterile or are sexually inactive, and;
- •4. Subjects must be willing and able to participate in the trial and provide written informed consent.
排除标准
- •1. The subject experienced a clinically significant adverse effect to attributable to Investigational Medicinal Product (IMP) during a previous trial that could put the subject at risk for further treatment with safinamide.
- •2. If female, the subject is pregnant or lactating.
- •3. Any medical issues, which have emerged since the initial clinical trial, that in the opinion of the investigator precludes a subject?s ability to participate in this open-label trial.
研究者
相似试验
进行中（未招募）
不适用
Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease PatientsIdiopathic Parkinson's DiseaseMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2008-005492-94-FIewron Pharmaceuticals1,285
进行中（未招募）
1 期
Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease PatientsIdiopathic Parkinson's DiseaseMedDRA version: 14.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2008-005492-94-NLMerck Serono S.A. - Geneva1,285
进行中（未招募）
不适用
Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease PatientsIdiopathic Parkinson's DiseaseMedDRA version: 15.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2008-005492-94-ATewron Pharmaceuticals1,285
进行中（未招募）
1 期
Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease PatientsIdiopathic Parkinson's DiseaseMedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2008-005492-94-BEMerck Serono S.A. - Geneva1,285
进行中（未招募）
不适用
Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease PatientsIdiopathic Parkinson's DiseaseMedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2008-005492-94-HUMerck Serono S.A. - Geneva1,285